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Abstract
Objective To examine the safety of using aliskiren combined with agents
used to block the renin-angiotensin system.
Design Systematic review and meta-analysis of randomised controlled
trials.
Data sources Medline, Embase, the Cochrane Library, and two trial
registries, published up to 7 May 2011.
Study selection Published and unpublished randomised controlled trials
that compared combined treatment using aliskiren and angiotensin
converting enzyme inhibitors or angiotensin receptor blockers with
monotherapy using these agents for at least four weeks and that provided
numerical data on the adverse event outcomes of hyperkalaemia and
acute kidney injury. A random effects model was used to calculate pooled
risk ratios and 95% confidence intervals for these outcomes.
Results 10 randomised controlled studies (4814 participants) were
included in the analysis. Combination therapy with aliskiren and
angiotensin converting enzyme inhibitors or angiotensin receptor blockers
significantly increased the risk of hyperkalaemia compared with
monotherapy using angiotensin converting enzymes or angiotensin
receptor blockers (relative risk 1.58, 95% confidence interval 1.24 to
2.02) or aliskiren alone (1.67, 1.01 to 2.79). The risk of acute kidney
injury did not differ significantly between the combined therapy and
monotherapy groups (1.14, 0.68 to 1.89).
Conclusion Use of aliskerin in combination with angiotensin converting
enzyme inhibitors or angiotensin receptor blockers is associated with
an increased risk for hyperkalaemia. The combined use of these agents
warrants careful monitoring of serum potassium levels.
Introduction
Blockade of the renin-angiotensin system using angiotensin
converting enzyme (ACE) inhibitors and angiotensin receptor
blockers has been advocated for the management of congestive
heart failure, hypertension, and proteinuria.
1 2 The opportunity
to block the renin-angiotensin system at multiple foci has a
compelling biological rationale but may be associated with
significant toxicity.
3-6
Direct inhibition of renin—the most proximal aspect of the
renin-angiotensinsystem—becameclinicallyfeasiblefrom2007
with the introduction of aliskiren (Rasilez; Novartis
Pharmaceuticals, Switzerland). Aliskiren has been shown to be
efficacious for the management of hypertension, congestive
heart failure, and proteinuria either as monotherapy
7 8 or in
combination with ACE inhibitors or angiotensin receptor
blockers.
9-12 In Ontario, Canada (estimated population 13
million), the use of aliskiren has increased from 56 603
individual prescriptions in 2009 to 119 891 in 2010.
13
The publication of the Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial
(ONTARGET) highlighted the danger of dual inhibition of the
renin-angiotensin system, reporting an increased risk of acute
Correspondence to: Z Harel harelz@smh.ca
Extra material supplied by the author (see http://www.bmj.com/content/344/bmj.e42?tab=related#webextra)
Details of search strategy and
Risk of bias in included trials
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e42 doi: 10.1136/bmj.e42 (Published 9 January 2012) Page 1 of 13
Research
RESEARCHdialysisandhyperkalaemiainpatientsprescribedACEinhibitors
and angiotensin receptor blockers together.
5 These results led
scientificorganisationstocautionagainsttheuseofcombination
therapy using ACE inhibitors and angiotensin receptor
blockers.
14-17 As a blocker of the renin-angiotensin system,
aliskirenmaybeassociatedwithsimilaradverseeffectsasACE
inhibitors and angiotensin receptor blockers, especially when
usedincombinationwiththeseagents.Hyperkalaemiaandacute
kidney injury constitute the most serious consequences of
blocking the renin-angiotensin system and have been shown to
lead to increased morbidity and mortality.
18-20 To date, most
trials comparing combination therapy with aliskiren and
renin-angiotensin system blockers have focused on surrogate
outcomes and have been underpowered to provide robust
estimates of adverse events.
9 11 21-25
Given the increasing popularity of aliskiren, particularly in
combination with other renin-angiotensin system blockers, it is
important to determine whether its use in combination with
theseagentsisassociatedwithpotentiallylifethreateningsafety
events. We carried out a systematic review and meta-analyses
ofthesafetyofusingaliskirencombinedwithanACEinhibitor
or angiotensin receptor blocker.
Methods
Weusedastrategydevelopedwithahealthinformaticsspecialist
(see web extra on bmj.com) to search Ovid Medline (1948 to 7
May 2011), Embase (1980 to 7 May 2011), and the Cochrane
central register of controlled trials (1993 to 7 May 2011). No
language restrictions were applied and we reviewed the
bibliographies of identified articles to locate further eligible
studies. In addition we searched the Clinical trials registry
(www.clinicaltrials.gov), the Novartis clinical trial results
database, and abstracts of the past five years from conferences
oftheAmericanSocietyofNephrologyandtheEuropeanRenal
Association for ongoing or completed trials.
Study selection and validity assessment
We included all randomised controlled clinical trials of at least
four weeks’ duration involving aliskiren in combination with
either ACE inhibitors or angiotensin receptor blockers that
provideddataontheincidenceofhyperkalaemiaoracutekidney
injuryrelativetomonotherapywithaliskiren,anACEinhibitor,
or an angiotensin receptor blocker. Where necessary we
contacted corresponding authors for additional missing data.
For crossover studies, we used only the first phase.
All dosing regimens of aliskiren, ACE inhibitors, and
angiotensin receptor blockers were considered, and all ACE
inhibitors and angiotensin receptor blockers used in clinical
practice were eligible for inclusion. For the purpose of the
analysesweconsideredACEinhibitorsandangiotensinreceptor
blockers together as one class.
We excluded drug combinations with agents other than ACE
inhibitors and angiotensin receptor blockers—for example,
combined telmisartan and hydrochlorothiazide. Studies that
enrolledpatientswhowerereceivingchronicdialysisandstudies
published only as abstracts were excluded. We also excluded
one study with missing information that could not be obtained
from the authors.
26 Where more than one publication of a trial
existedorwhenaretrospectivesubgroupanalysiswaspublished
we used the most complete publication. Studies for which risk
of bias could not be determined in any of the domains of our
assessment were excluded. We also excluded observational
studies, case series, letters, commentaries, reviews, and
editorials.
Twoauthors(ZHandCG)scannedtitlesandabstractsforinitial
selection. Selected articles were reviewed in full and
independentlyassessedforeligibilitybythesametworeviewers.
Discrepancies were resolved by consensus.
Outcome measures
The primary outcome was hyperkalaemia, defined as a serum
potassiumconcentrationgreaterthan5.5mmol/L(meq/L).The
secondary outcomes included acute kidney injury, defined as a
serumcreatinineconcentrationgreaterthan176.8µmol/L(>2.0
mg/dL), and the severity of hyperkalaemia stratified into
moderate(serumpotassiumconcentration5.5-5.9mmol/L)and
severe (≥6.0 mmol/L).
Assessment of risk of bias
Two reviewers (ZH and CG) independently assessed the risk
of bias in the included studies without blinding to authorship
or journal by using the predefined checklist of the Cochrane
Database of Systematic Reviews.
27 The checklist assessed risk
ofbiasinsequencegeneration,allocationconcealment,blinding,
attrition, selection bias, and other biases. In particular, because
we were assessing the risk of adverse outcomes, for the domain
of attrition we evaluated studies for attrition in reporting
outcomes of interest and not the primary outcome of the study.
In the domain of other biases, we determined whether an
assessment of adverse effects was planned a priori. The
classification in each category was yes, no, or unclear. We
carried out an overall assessment of the risk of bias based on
the responses for the selected criteria. Discrepancies were
resolved by consensus and involvement of the other reviewers.
Data extraction and synthesis
Two reviewers (ZH and CG) independently extracted data by
using custom made data extraction forms. Disagreements were
resolvedbyconsensus.Theoriginaldatawerenotmodifiedand
we carried out calculations from the available data for the
meta-analysis. For binary outcome variables (hyperkalaemia
and acute kidney injury) we calculated risk ratios, risk
differences, and numbers needed to harm (NNH), along with
95% confidence intervals. As we anticipated clinical and
statistical heterogeneity, we used a random effects model
because it accounts to an extent for variability within and
between studies. Statistical heterogeneity was assessed using
the Cochrane Q test (significance set at 0.01) and by I² values.
We evaluated publication bias using the funnel plot method.
Subgroup and sensitivity analyses
We planned subgroup analyses to assess for clinical
heterogeneity stemming from the characteristics of our study
populationsandourinterventions.Thesecharacteristicsincluded
age, sex, comorbidities (chronic kidney disease, proteinuria,
congestive heart failure, diabetes), and dose of aliskiren used.
Retrospective sensitivity analysis was done on the outcome of
severe hyperkalaemia, stratified by patient risk for
hyperkalaemia into low and high risk groups. Patients at high
risk for hyperkalaemia were those with attributes that
predisposedthemtohyperkalaemia(forexample,chronickidney
disease, diabetes, decompensated heart failure, intravascular
volume depletion), or concomitant treatment with drugs that
may contribute to hyperkalaemia (for example, β blockers,
potassiumsparingdiuretics,aldosteroneantagonists).Sensitivity
analyses were planned to assess effects after removal of outlier
studies identified in funnel plots.
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RESEARCHResults
Overall, 841 screened citations met the search criteria. After
excluding 38 duplicate citations, 803 citations were evaluated,
of which 77 were reviewed in detail. Ten eligible randomised
controlled studies were identified and included in this review
(fig 1⇓).
9 11 21-25 28-30
Study participants and interventions
Table 1⇓ summarises the characteristics of the included studies
and participants. Of the 10 included studies, seven compared
thecombinationofaliskirenandanangiotensinreceptorblocker
(valsartan, losartan, or irbesartan) with monotherapy using an
angiotensin receptor blocker,
11 21 23-25 28 30 with five of these
studies comparing combination therapy with aliskiren
monotherapy.
11 21 24 25 28 Two studies compared the combination
of aliskiren and unspecified ACE inhibitors or angiotensin
receptor blockers with their respective ACE inhibitors or
angiotensin receptor blocker monotherapy,
9 22 and one study
compared the combination of aliskiren and an ACE inhibitor
with ACE inhibitor or aliskiren monotherapy.
29 The dosing
regimensforaliskiren,ACEinhibitors,andangiotensinreceptor
blockers varied among studies; however, nearly all included
studies were designed to reach the maximum recommended
doses for aliskiren and the corresponding ACE inhibitors or
angiotensinreceptorblockers.Studydurationrangedfromeight
to36weeks.Participantsweremostlymaleandrelativelyyoung.
The studies did not include patients with a history of severe
renalimpairment.Concurrentantihypertensivetherapywasused
in six studies, including β adrenergic receptor antagonists in
four
9 22 23 25 and aldosterone antagonists in two.
9 22 Most studies
included frequent safety assessments of laboratory data; only
two studies, however, reported predefined safety outcomes.
9 30
Risk of bias
The risk of bias was low (see web extra on bmj.com). Seven
studies described the methods used for generation of the
randomisationsequence,whereassixadequatelyreporteddetails
about allocation concealment. All studies reported blinding of
participants and investigators, but only six provided sufficient
detailonthemethodsusedtomaskstudystaff,participants,and
assessors. This is unlikely to affect safety outcomes, however,
as these were based on objective laboratory data. Although
safety events were monitored and recorded for all included
studies,onlytwostudiesprovideddefinitionsofsuchoutcomes
apriori.Regardless,completedataforhyperkalaemiaandacute
kidney injury were available for 10 and eight studies,
respectively. Withdrawal rates for all studies were less than
20%. All included studies were sponsored by Novartis
Pharmaceuticals, the manufacturer of aliskiren.
Outcomes
Hyperkalaemia
Ten studies reported on the outcome of hyperkalaemia (table
2⇓ and fig 2⇓). All compared the combination of aliskiren and
an ACE inhibitor or an angiotensin receptor blocker with
monotherapy using an ACE inhibitor or angiotensin receptor
blocker (n=4814). Six studies also compared the combination
of aliskiren and an ACE inhibitor or an angiotensin receptor
blocker with aliskiren monotherapy (n=2974), and six reported
on both comparisons. The risk of hyperkalaemia was
significantly higher among participants given aliskiren in
combination with an ACE inhibitor or angiotensin receptor
blocker than among those given ACE inhibitor or angiotensin
receptor blocker monotherapy (relative risk 1.58, 95%
confidence interval 1.24 to 2.02; risk difference 0.02, 95%
confidence interval 0.01 to 0.04; number needed to harm 43,
95% confidence interval 28 to 90; I
2=0%). Similarly, the risk
of hyperkalaemia from combined use of aliskiren and an ACE
inhibitororangiotensinreceptorblockercomparedwithaliskiren
monotherapy was significantly increased (relative risk 1.67,
1.01 to 2.79; risk difference 0.02, 0.03 to 0.01; NNH 50, 33 to
125; I
2=19%).
Acute kidney injury
Eight studies reported on acute kidney injury as an outcome
measure (fig 3⇓). Six compared the combination of aliskiren
and an ACE inhibitor or angiotensin receptor blocker with
aliskiren monotherapy (n=3063), and eight compared the
combination of aliskiren and an ACE inhibitor or angiotensin
receptor blocker with ACE inhibitor or angiotensin receptor
blocker monotherapy (n=4345); five studies reported on both
comparisons. The risk of acute kidney injury was not
significantly increased among participants given aliskiren in
combination with an ACE inhibitor or angiotensin receptor
blocker than among those given ACE inhibitor or angiotensin
receptor blocker monotherapy (relative risk 1.14, 95%
confidence interval 0.68 to 1.89; I
2=30%) or aliskiren
monotherapy (0.80, 0.31 to 2.04; I
2=0%).
Moderate and severe hyperkalaemia
TenstudiescomparedthecombinationofaliskirenandanACE
inhibitor or angiotensin receptor blocker with ACE inhibitor or
angiotensin receptor blocker monotherapy (n=4814), and six
compared combination therapy with aliskiren monotherapy
(n=2974; fig 4⇓). Combination therapy was associated with a
significantlyincreasedriskofmoderatehyperkalaemiacompared
withACEinhibitororangiotensinreceptorblockermonotherapy
(relative risk 1.85, 1.18 to 2.91; risk difference 0.02, 0.01 to
0.03; NNH 50, 33 to 100) as well as aliskiren monotherapy
(relative risk 4.04, 2.12 to 7.71; risk difference 0.03, 0.02 to
0.04; NNH 33, 25 to 50). In contrast, the risk for severe
hyperkalaemia did not differ with use of combination therapy
compared with monotherapy with an ACE inhibitor or
angiotensin receptor blocker (relative risk 1.12, 0.55 to 2.29)
or monotherapy with aliskiren (0.45, 0.53 to 1.53).
Subgroup and sensitivity analysis
Planned subgroup analyses were not possible from available
data, and patient level data could not be obtained. A
retrospectivesensitivityanalysiswascarriedoutontheoutcome
severe hyperkalaemia, stratifying patients by their risk of
hyperkalaemia into low and high risk groups (fig 5⇓). Seven
studiesenrolledpatientsathighriskforhyperkalaemia(n=3141)
and three enrolled patients at low risk (n=1673). Meta-analysis
found that combination therapy did not significantly increase
the risk for severe hyperkalaemia in both groups: relative risk
inhighriskpatients1.32(95%confidenceinterval0.64to2.74)
and in low risk patients 0.42 (0.08 to 2.14).
Publication bias
No evidence of publication bias for the primary outcome was
suggestedbyvisualinspectionofthefunnelplots(seewebextra
fig 1). The effect of two outlying studies on the hyperkalaemia
outcome were assessed using a sensitivity analysis. Removal
of each of these studies decreased the magnitude of the effect
for the risk of hyperkalaemia using combination therapy with
aliskiren and ACE inhibitors or angiotensin receptor blockers
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RESEARCHcompared with monotherapy with an ACE inhibitor or
angiotensinreceptorblocker(relativerisk1.51,95%confidence
interval 1.17 to1.95) or monotherapy with aliskiren (1.62, 0.91
to 2.87).
Discussion
Inthissystematicreview,weidentifiedasignificantlyincreased
risk of hyperkalaemia among people prescribed aliskiren
(Rasilez;NovartisPharmaceuticals,Switzerland)incombination
withanACEinhibitororangiotensinreceptorblockercompared
with those prescribed monotherapy using aliskiren, an ACE
inhibitor, or angiotensin receptor blocker. This risk was about
50%greaterinthoseprescribedcombinationtherapythanamong
those receiving ACE inhibitors or angiotensin receptor blocker
monotherapy, and was about 70% greater in those prescribed
combination therapy than among those receiving aliskiren
monotherapy.Wefoundnoevidenceofasignificantdifference
in the risk of acute kidney injury between the study groups.
Todate,nopublishedsystematicreviewsormeta-analyseshave
evaluated the safety of combination therapy with aliskiren and
ACE inhibitors or angiotensin receptor blockers. Previously
published pooled analyses of the safety of aliskiren have
provided discordant conclusions.
31 32 This may have resulted
from clinical and methodological heterogeneity between these
studies. Our findings differ from those reported previously by
one study,
31 which showed no difference in the incidence of
hyperkalaemia with combined aliskiren and valsartan therapy.
However,onlythreeofthetrialsweanalysedwerealsoanalysed
by that study. In accordance with our results, another study
32
concluded that the incidence of hyperkalaemia was higher in
thoseusingcombinedaliskirenandangiotensinreceptorblockers
comparedwiththoseusingangiotensinreceptorblockersalone.
We included the studies evaluated by these two reviews and
incorporated findings from six recently completed randomised
trials.
The studies included in this meta-analysis show variable
statistical and clinical heterogeneity. Given that this
meta-analysis focused on adverse events, which are relatively
infrequentoutcomes,thenoticeableclinicalheterogeneityamong
theincludedstudieswastobeexpected.Thepopulationsstudied
variedwidelyandincludedpatientswithhypertension,diabetes,
congestive heart failure, and recent acute coronary syndrome.
Although including such a heterogeneous group may increase
the generalisability of our review, it may also bias the results
because these populations possess differential risks for
hyperkalaemia and acute kidney injury. However, patients at
high risk for hyperkalaemia and acute kidney injury represent
an important segment of current clinical practice and their
exclusion makes little sense.
Our stratified analysis of hyperkalaemia by severity showed
that combination therapy was associated with a significantly
increased risk of moderate but not severe hyperkalaemia. To
further explore any heterogeneity in the risk of severe
hyperkalaemia, we assessed high and low risk populations in a
retrospective sensitivity analysis. The lack of an increased risk
of severe hyperkalaemia persisted in both populations, in
contrast with previous studies that showed an increased risk of
hyperkalaemia associated morbidity and mortality among high
risk patients, owing to the interaction of multiple blockers of
therenin-angiotensinsystemthatwasaccentuatedbyotherdrugs
andcoexistingconditions.
14 15Ourresultsmayalsobeexplained
bytheclosefollow-upofparticipants,whichmayhavemitigated
any differences in baseline risk through adjustments in the
management of participants with moderate hyperkalaemia.
The lack of a significantly increased risk of acute kidney injury
in our meta-analysis is interesting. Drugs used to block the
renin-angiotensinsystemaffectrenalhaemodynamicsprimarily
through dilation of the efferent arteriole, leading to reduced
intraglomerular pressure.
29-31 As with hyperkalaemia, certain
populations possess an increased risk for acute kidney injury
owingtopre-existingcomorbidityandtheuseofdrugsthatmay
contributetointravascularvolumedepletion.Thesefactorsmay
potentiatetheeffectsofrenin-angiotensinsystemblockadeusing
drugs. Aside from the Aliskiren Study in Post-MI patients to
ReducerEmodelling(ASPIRE)study,
22highriskpatientsinour
studyhadadecreasedriskofacutekidneyinjurycomparedwith
their low risk counterparts. As with hyperkalaemia, this trend
may result from close follow-up in addition to an extremely
conservative serum creatinine threshold used to define acute
kidney injury in the included studies, which may have missed
many milder cases of acute kidney injury. In fact, current
definitions of acute kidney injury, such as the Acute Kidney
Injury Network and RIFLE (Risk, Injury, Failure, Loss and
End-Stage Renal Disease) criteria, identify acute kidney injury
by increases in serum creatinine concentration as small as 26.8
µmol/L (0.3 mg/dL).
33 Finally, the relatively short duration of
follow-upintheincludedstudiesmayhavealsounderestimated
the true incidence of acute kidney injury. Hyperkalaemia often
ensues shortly after receipt of a renin-angiotensin system
blockingagent,whereasacutekidneyinjuryusuallyoccurslater
after a superimposed renal insult. The short duration of
follow-up may have thereby missed these late events.
Quality of the evidence
Most of the trials included in the review were of good quality.
A methodological consideration that may have affected study
results is the potential lack of standardisation of the creatinine
assays among the included studies, which was reported in only
two studies.
10 20 As there are four assays currently in use to
measureserumcreatininelevels,eachwithdifferentperformance
characteristics, measurement bias may have been introduced
when the studies were pooled.
Strengths and limitations of the review
Ourreviewhasseveralstrengths.Itisthefirstreviewdescribing
safety problems associated with use of aliskiren. Our search
strategy was broad and included published as well as
unpublished sources to capture all safety events. Two
independent investigators also rigorously assessed
methodological quality.
Our study also has several limitations. We pooled the results of
a group of studies that were not originally intended to explore
safety outcomes. Many of these included studies were small,
resultinginfewadversesafetyevents.Asaresult,theconfidence
intervals for the risk ratios for hyperkalaemia and acute kidney
injuryforindividualstudieswerewide;however,meta-analytical
estimates were not met with wider uncertainty. Furthermore,
we did not have access to original data for any of these studies
and included participants who were clinically heterogeneous.
Thus we were unable to account for all important differences
in the risk for hyperkalaemia and acute kidney injury between
different groups. It is notable that most patients had preserved
baselinekidneyfunction,whichmayhavelimitedthelikelihood
of hyperkalaemia and acute kidney injury, even among those
exposedtorenin-angiotensinsystemblockadeusingcombination
therapy.
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RESEARCHImplications for practice and future research
Thusfar,combinationtherapywithaliskirenandACEinhibitors
or angiotensin receptor blockers has shown efficacy only on
surrogate end points.
9 19 23 Trials evaluating the effect of
combinationtherapywithaliskirenonimportantoutcomeshave
yet to be published. The Aliskiren Trial in Type 2 Diabetes
Using Cardiovascular and Renal Disease Endpoints
(ALTITUDE) and Efficacy and Safety of Aliskiren and
Aliskiren/EnalaprilCombinationonMorbi-mortalityinPatients
With Chronic Heart Failure (ATMOSPHERE) trials will
evaluate and clarify the role of combination therapy with
aliskiren and ACE inhibitors on important clinical outcomes;
thus providing clinicians with useful insights into the rational
use of such therapy.
34 35 Until that time, patients receiving
combinationtreatmentincludingaliskirenforrenin-angiotensin
systemblockadewarrantcarefulmonitoringofserumpotassium
levels. Additionally, although an increased risk for severe
hyperkalaemia was not shown in our meta-analysis, our review
included randomised controlled trials that enrolled carefully
selected populations with relatively preserved kidney function.
As such, the generalisability of our findings (and particularly
the risk for severe hyperkalaemia) to routine clinical practice
is unknown. As such, applying our findings into real world
practice must be done with caution as there is a danger of
extrapolating the findings of landmark clinical trials to patients
who may be at increased risk of adverse events.
14
Conclusion
The use of aliskiren in combination with ACE inhibitors or
angiotensin receptor blockers is associated with a significantly
increased risk of hyperkalaemia compared with monotherapy
usingACEinhibitorsorangiotensinreceptorblockers.Wefound
no effect of combination therapy on the risk of acute kidney
injury. Further research to clarify the role and safety of using
aliskirenincombinationtherapyonimportantclinicaloutcomes
is needed.
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RESEARCHWhat is already known on this topic
Blockers of the renin-angiotensin system (RAS), such as aliskiren, are used to manage many conditions, including congestive heart
failure, hypertension, and proteinuria
Hyperkalaemia and acute kidney injury are serious consequences of RAS blockade using combination therapy, leading to increased
morbidity and mortality
Most trials comparing combination therapy with aliskiren and other RAS blockers have focused on surrogate outcomes and have been
underpowered to provide robust estimates of adverse events
What this study adds
Combined use of aliskiren with angiotensin converting enzyme inhibitors or angiotensin receptor blockers is associated with a significantly
increased risk of hyperkalaemia compared with monotherapy with either drugs
Further research to clarify the role and safety of combination therapy with aliskiren on important clinical outcomes is needed before
widespread use can be advocated
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RESEARCHTables
Table1| Summary of studies included in meta-analysis of safety of combined aliskiren with angiotensin converting enzyme (ACE) inhibitors
or angiotensin receptor blockers (ARBs)
Safety
assessment
Safety
outcomes
Concurrent
antihypertensive
treatment
Study
population
Mean
baseline
estimated
Diabetes
(%)
Male
(%)
Mean
age
(years)
Study
duration
(weeks)
Targeted
dose (mg) Intervention Study
during
study
GFR
(ml/min)
Weeks 1, 3,
4, 6, 7, and
9-11
No primary or
secondary
safety
outcomes
Diuretics, calcium
channel blockers,
vasodilator, α
blockers
Hypertension;
bodymassindex
>25; left
ventricular
hypertrophy on
echocardiogram
87; 83; 85 23; 22;
27
73;
77;
77
58; 59;
59
36 300; 10;
300/100
Aliskiren; losartan;
aliskiren and
losartan
ALLAY
2009
17
Weeks 2, 4,
8, and 12
Primary
outcome of
hyperkalaemia
and acute
kidney injury
β blockers,
aldosterone
antagonists
History of
hypertension;
NHYA class 2-4
congestive heart
failure; brain
natriuretic
70; 68 31; 30 80;
76
67; 68 12 150; NA Aliskiren; placebo ALOFT
2008
9
peptide >100
pg/mL; stable
dose of ACE
inhibitor or ARB
and β blocker
Unclear No primary or
secondary
safety
outcomes
β blockers,
aldosterone
antagonists
2-8 weeks after
AMI; stable dose
of ACE or ARB;
left ventricular
ejection fraction
<45% and
80; 81 23; 22 81;
85
61; 59 36 300; NA Aliskiren; placebo ASPIRE
2011
22
infarct size
≥20% on
echocardiogram
Weeks 1, 2,
and 4-8
No primary or
secondary
safety
outcomes
β blockers,
calcium channel
blockers, diuretics
Documented
acute coronary
syndrome;
raised brain
natriuretic
peptide levels
76; 75; 74;
76
19; 21;
21; 20
68;
73;
69;
63
63; 64;
63; 63
8 300; 320;
300/320;
NA
Aliskiren; valsartan;
aliskiren and
valsartan; placebo
AVANTE
GARDE
2010
25
3-10 days after
acute coronary
syndrome;
clinically stable
Weeks 1 ,4,
8, 11, 12, 16,
and 24
No primary or
secondary
safety
outcomes
Diuretics, calcium
channel blockers,
vasodilator, α
blockers, β
blockers
Diabetes
mellitus type 2;
diabetic
nephropathy
67; 69 100; 100 74;
68
62; 60 24 100;
300/100
Losartan; aliskiren
and losartan
AVOID
2008
19
Weeks 2, 4,
6, and 8
No primary or
secondary
safety
outcomes
None Stage I-II
hypertension
NA NA 58;
62;
62;
61
52; 52;
52; 53
8 300; 320;
300/320;
NA
Aliskiren; valsartan;
aliskiren and
valsartan; placebo
Oparil
2007
23
At conclusion
of study
No primary or
secondary
safety
outcomes
Diuretics Diabetes
mellitus 2; urine
albumin
excretion rate
>100 mg/24
hours; blood
NA 100; 100;
100; 100
63;
78;
86;
78
60; 59;
61; 61
8 300; 300;
300/300;
NA
Aliskiren; irbesartan;
aliskiren and
irbesartan; placebo
Persson
2009
20
pressure
>135/85 mm Hg;
GFR >40
mL/min
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RESEARCHTable 1 (continued)
Safety
assessment
during
study
Safety
outcomes
Concurrent
antihypertensive
treatment
Study
population
Mean
baseline
estimated
GFR
(ml/min)
Diabetes
(%)
Male
(%)
Mean
age
(years)
Study
duration
(weeks)
Targeted
dose (mg) Intervention Study
Weeks 1, 2,
4, 6, and 8
No primary or
secondary
None Mild to moderate
hypertension
NA 8; 7; 11;
2; 8
56;
55;
56; 56;
57; 57;
56
8 75/150/300;
80/160/320;
150/160
Aliskiren; valsartan;
aliskiren and
valsartan; aliskiren
Pool
2007
11
safety
outcomes
55;
61;
55
and
300/320;
and
hydrochlorothiazide;
placebo 150/12.5;
NA
Weeks 2, 4,
6, and 8
No primary or
secondary
safety
outcomes
None Diabetes
mellitus type 1
or 2; stage I-II
hypertension;
stable dose of
hypoglycaemic
drugs
NA 100; 100;
100
55;
60;
61
60; 60;
59
8 300; 10;
300/10
Aliskiren; ramipril;
aliskiren and ramipril
Uresin
2007
24
Weeks 2 and
8
Secondary
outcome of
safety and
tolerability of
combination
therapy
None Stage II
hypertension
NA 15; 17 47;
54
57; 57 8 320;
300/320
Valsartan; aliskiren
and valsartan
VANTAGE
2010
30
GFR=glomerular filtration rate; NA=not available; NYHA=New York Heart Association; AMI=acute myocardial infarction.
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RESEARCHTable 2| Number of primary and secondary events/total in included studies according to combination therapy or monotherapy
Acute kidney injury (creatinine >176.8 µmol/L) Hyperkalaemia (serum potassium >5.5 mmol/L)
Study Aliskiren
Aliskiren+ACE
inhibitor or ARB
ACE inhibitor
or ARB
Aliskiren+ACE
inhibitor or ARB Aliskiren
Aliskiren+ACE
inhibitor or ARB
ACE inhibitor or
ARB
Aliskiren+ACE
inhibitor or ARB
0/154 1/154 1/152 1/154 4/154 5/154 5/152 5/154 ALLAY 2009
17
NA NA 8/146 11/156 NA NA 12/146 13/156 ALOFT 2008
9
NA NA 5/397 15/422 NA NA 26/397 55/422 ASPIRE 2011
22
6/264 3/279 3/269 3/279 13/264 12/279 8/268 12/279 AVANTE GARDE
2010
25
NA NA 54/297 37/299 NA NA 32/297 41/299 AVOID 2008
19
1/417 4/426 2/445 4/426 7/416 18/424 7/443 18/424 Oparil 2007
23
0/7 0/7 NA NA 0/7 0/7 0/9 0/7 Persson 2009
20
1/532 0/278 0/177 0/172 2/532 2/178 0/177 2/178 Pool 2007
11
3/282 1/277 1/278 1/277 6/282 15/277 7/278 15/277 Uresin 2007
24
NA NA NA NA NA NA 0/219 0/232 VANTAGE 2010
30
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; NA=not available.
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RESEARCHFigures
Fig 1 Flow of studies through review
Fig 2 Risk of hyperkalaemia among participants given combined aliskiren and angiotensin converting enzyme (ACE) inhibitor
or angiotensin receptor blocker (ARB) versus monotherapy (ACE inhibitor, ARB, or aliskiren). Values less than 1.0 indicate
a decreased risk of outcome with combination therapy
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RESEARCHFig 3 Risk of acute kidney injury among participants given combined aliskiren and angiotensin converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB) versus monotherapy (ACE inhibitor, ARB, or aliskiren). Values less than 1.0
indicate a decreased risk of outcome with combination therapy
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RESEARCHFig 4 Risk of hyperkalaemia stratified by severity among participants given combination therapy with aliskiren and angiotensin
converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) versus monotherapy with ACE inhibitor or ARB.
Values less than 1.0 indicate a decreased risk of outcome with combination therapy
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RESEARCHFig 5 Risk of severe hyperkalaemia stratified by high and low risk participants given combination therapy with aliskiren and
angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) versus monotherapy with ACE inhibitor
or ARB. Values less than 1.0 indicate a decreased risk of outcome with combination therapy
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